Identification of Enhancer RNA CDK6-AS1 as a Potential Novel Prognostic Biomarker in Gastric Cancer

Identification of Enhancer RNA CDK6-AS1 as a Potential Novel Prognostic Biomarker in Gastric Cancer

Background: This study aimed to confirm the role of enhancer RNAs (eRNAs) in gastric cancer and their clinical utility.Methods: We used Cox survival and relevance analysis to identify the candidate eRNAs in gastric cancer and performed Gene Ontology and Reactome pathway enrichment to determine the p...

Full description

Bibliographic Details
Main Authors:	Shifeng Yang, Xiaoming Zou, Hao Yang, Jiacheng Li, Ange Zhang, Lisha Zhang, Changjian Li, Lei Zhu, Zhen Ma
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-04-01
Series:	Frontiers in Genetics
Subjects:	CDK6-AS1 CDK6 enhancer RNA gastric cancer prognostic biomarker
Online Access:	https://www.frontiersin.org/articles/10.3389/fgene.2022.854211/full

Similar Items

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
by: Mattia Garutti, et al.
Published: (2021-05-01)

Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review
by: Ioana-Miruna Stanciu, et al.
Published: (2023-04-01)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
by: Ran Sun, et al.
Published: (2022-04-01)

CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia
by: Wei Liu, et al.
Published: (2021-02-01)

The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
by: Emily Jiggens, et al.
Published: (2021-10-01)

CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
by: Yilan Yang, et al.
Published: (2020-09-01)

The Clinicopathological Significance of the Cyclin D1/E1–Cyclin-Dependent Kinase (CDK2/4/6)–Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers
by: Ayat Lashen, et al.
Published: (2024-04-01)

The Role of Cyclin-Dependent Kinases (CDK) 4/6 in the Ovarian Tissue and the Possible Effects of Their Exogenous Inhibition
by: Graziana Scavone, et al.
Published: (2023-10-01)

Analysis of Cyclin-Dependent Kinase 1 as an Independent Prognostic Factor for Gastric Cancer Based on Statistical Methods
by: Xu Zhang, et al.
Published: (2020-12-01)

Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
by: Navid Sobhani, et al.
Published: (2021-02-01)

CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers
by: ZHANG Baihong, et al.
Published: (2019-01-01)

CDK7 is a prognostic biomarker for non-small cell lung cancer
by: Christiane Kuempers, et al.
Published: (2022-09-01)

Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
by: Ioana-Miruna Stanciu, et al.
Published: (2023-03-01)

Regulation of the Cell Cycle by ncRNAs Affects the Efficiency of CDK4/6 Inhibition
by: Qingyi Hu, et al.
Published: (2023-05-01)

Cdk6: At the interface of Rb and p53
by: Sofie Nebenfuehr, et al.
Published: (2018-09-01)

Research Progress of CDK4/6 Inhibitors in Non-small Cell Lung Cancer
by: Qiong QIN, et al.
Published: (2020-03-01)

CDK5 promotes apoptosis and attenuates chemoresistance in gastric cancer via E2F1 signaling
by: Long-Long Cao, et al.
Published: (2023-11-01)

3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) Positron Emission Tomography as an In Vivo Biomarker of inhibition of CDK 4/6-Rb pathway by Palbociclib in a patient derived bladder tumor
by: James L. Tatum, et al.
Published: (2022-08-01)

Pax6 Lengthens G1 Phase and Decreases Oscillating Cdk6 Levels in Murine Embryonic Cortical Progenitors
by: Da Mi, et al.
Published: (2018-11-01)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
by: Kamal Pandey, et al.
Published: (2020-11-01)

Carboxypeptidase vitellogenic like facilitates resistance to CDK4/6 inhibitors in breast cancer
by: Xiang Zhu, et al.
Published: (2023-04-01)

Atypical teratoid/rhabdoid tumour with CDK6 amplification in a child: a case report and literature review
by: Zhibin Li, et al.
Published: (2023-08-01)

Recent Progress in CDK4/6 Inhibitors and PROTACs
by: Hao Wang, et al.
Published: (2023-12-01)

MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment
by: Angeliki Andrikopoulou, et al.
Published: (2021-08-01)

CDK6 is essential for mesenchymal stem cell proliferation and adipocyte differentiation
by: Alexander J. Hu, et al.
Published: (2023-08-01)

The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors
by: Federico Sottotetti, et al.
Published: (2022-09-01)

CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
by: Lisa Scheiblecker, et al.
Published: (2020-11-01)

CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges
by: Tatjana Arsenijevic, et al.
Published: (2023-02-01)

The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer
by: Chen Liu, et al.
Published: (2022-01-01)

Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2− Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies
by: Abeer J. Al-Qasem, et al.
Published: (2021-10-01)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
by: Ilenia Migliaccio, et al.
Published: (2021-05-01)

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
by: Amelia McCartney, et al.
Published: (2019-07-01)

CDK 4/6 inhibitors combined with radiotherapy: A review of literature
by: Claire Bosacki, et al.
Published: (2021-01-01)

LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer
by: Xi Jin, et al.
Published: (2020-05-01)

Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer
by: Joseph J. Zhao, et al.
Published: (2023-09-01)

GPR37 promotes cancer growth by binding to CDK6 and represents a new theranostic target in lung adenocarcinoma
by: Xiaona Xie, et al.
Published: (2022-09-01)

CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in <i>KIT</i> D816V<sup>+</sup> Neoplastic Mast Cells
by: Mathias Schneeweiss-Gleixner, et al.
Published: (2022-06-01)

Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro
by: Xi-Feng Jin, et al.
Published: (2021-03-01)

Poly(rC) binding protein 2 (PCBP2) promotes the viability of human gastric cancer cells by regulating CDK2
by: Changyu Chen, et al.
Published: (2018-05-01)

Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients
by: Vicenç Ruiz de Porras, et al.
Published: (2019-10-01)